| Acceptance rate | 46% |
|---|---|
| Time to first decision | 6 months* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
ACTA Pharmaceutica Sciencia
2011 , Vol 53 , Num 4
FORMULATION AND EVALUATION OF GATIFLOXACIN NIOSOMES USING SORBITAN MONOESTERS
Department of Pharmaceutics, Devaki Amma Memorial College of Pharmacy Chelembra, Kerala, India
Viewed :
15995
-
Downloaded :
4420
Niosomes have been assuring as a cheap and chemically stable alternative to liposomes. In the present study, gatifloxacin niosomes were formulated by thin film hydration technique in two different ratios of Span surfactant, cholesterol and DCP (47.5:47.5:5 and 60:30:10) and evaluated for their particle size, zeta potential, surface morphology, entrapment efficiency, in vitro drug release and in vivo pharmacokinetic studies. The formulated niosomes were shown multi lamellar vesicles in the size range of 3.3-4.1 μm. Zeta potential values of two different ratios of gatifloxacin niosomes were found to be in the region -9 to -13 mV. Surface morphology examinations of the prepared niosomes by scanning electron microscope have shown that niosomes are spherical in shape and uniform in size. The in vitro release studies of gatifloxacin niosomes in the ratio of 47.5:47.5:5 exhibited cumulative drug release of 96.17% in 24 hours. The in vitro release data displayed; the gatifloxacin niosomes is sustained release dosage form and also obey or follow the first order of kinetics. Gatifloxacin niosome were stable, and didn’t show any physicochemical changes for 3 months at 40°C and 75% RH. Pharmacokinetics studies of gatifloxacin niosomes made with Span 60 were shown increased Cmax AUC, AUMC, t1/2 and MRT values compared with marketed intravenous gatifloxacin product. The improved pharmacokinetic parameters and stability of formulated gatifloxacin niosomes with Span 60 have exhibited prolonged action and improvement bioavailability over the conventional form which might be to improve the patient compliance and reduce the side effects.
Keywords :
GATIFLOXACIN, SPAN - 40 - 60 - 80, NIOSOMES, ENTRAPMENT EFFICIENCY, RELEASE RATE, PHARMACOKINETIC STUDIES